Zanidatamab
- Generic Name
- Zanidatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169946-15-8
- Unique Ingredient Identifier
- Z20OC92TDI
- Background
According to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to significant anti-tumo...
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06695845
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- 🇺🇸
USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Washington Cancer Center, Washington, District of Columbia, United States
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, United States
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 168
- Registration Number
- NCT06043427
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 54
- Registration Number
- NCT05868226
- Locations
- 🇺🇸
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States
Personalized Medicine for Advanced Biliary Cancer Patients
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 800
- Registration Number
- NCT05615818
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven, Leuven, Belgium
🇫🇷CHU Amiens Picardie, Amiens, France
🇫🇷CHU d'Angers, Angers, France
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 918
- Registration Number
- NCT05152147
- Locations
- 🇦🇷
Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina
🇦🇷Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05035836
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT05027139
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸UC San Diego - Moores Cancer Center, La Jolla, California, United States
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT04578444
- Locations
- 🇫🇷
Jean Minjoz Hospital, Besançon, France
🇫🇷Hopital Haut-Leveque - CHU Bordeaux, Pessac, France
🇫🇷Gustave Roussy Cancer Center, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.